Posted by Michael Wonder on 17 May 2017
Brexit’s potential health benefits
16 May 2017 - An opportunity exists to modify outdated regulatory system specifically for the UK.
The UK’s Brexit decision will have significant disruptive effects on medicines regulation and the future of the pharmaceutical industry. But it also offers some potential advantages if politicians and policymakers commit firmly to an alternative course.
The UK will be denied early access to important new medicines approved on a European basis, and will no longer take part in EU-wide clinical trials used in the assessment of products such as orphan drugs. Companies will have to make separate applications to the UK for product approval for a much smaller population. Some argue they will not bother with the UK or at least file later, slowing access to new medicines.
